CLAIMS

1. A vector, which comprises an adeno-associated virus (AAV) genome or a derivative thereof and a polynucleotide sequence encoding REP1 or a variant thereof.
2. A vector according to claim 1, wherein said derivative is a chimeric, shuffled or capsid modified derivative.
3. A vector according to claim 1 or 2, wherein said AAV genome is from a naturally derived serotype or isolate or clade of AAV.
4. A vector according to claim 3, wherein said serotype is AAV serotype 2 (AAV2).
5. A vector according to claim 4, which comprises SEQ ID NO: 1 or a derivative thereof.
6. A vector according to any one of the preceding claims, wherein said polynucleotide sequence encodes a polypeptide having at least 70% homology to SEQ ID NO: 3 over its entire sequence.
7. A vector according to claim 6, wherein said polynucleotide sequence has at least 70% homology to SEQ ID NO: 2 over its entire sequence.
8. A vector according to any one of the preceding claims, which comprises a promoter sequence operably linked to said polynucleotide sequence encoding REP1 or a variant thereof.
9. A vector according to claim 8, wherein said promoter is constitutively active.
10. A vector according to claim 8, wherein expression from said promoter is retinal-cell specific.
11. A vector according to any one of the preceding claims, which comprises one or more additional regulatory sequences.
12. A vector according to claim 11, which comprises a sequence having at least 70% homology to SEQ ID NO: 5 over its entire sequence.

13. Use of a vector according to any one of claims 1-12 in the manufacture of a medicament for ~~A method of~~ treating or preventing choroideremia in a patient in need thereof; ~~, comprising administering a therapeutically effective amount of a vector according to any one of the preceding claims~~ wherein the vector is to be administered to said patient by direct retinal, subretinal or intravitreal injection. ~~, and thereby treating or preventing choroideremia in said patient.~~

14. The use ~~A method~~ according to claim 13, wherein said vector is to be administered directly into the subretinal space.